Superworth

Regeneron Pharmaceuticals price to free cash flow REGN

Market value divided by free cash flow over the last twelve months, since 2013.

Today, Nov 3, 2026
26.6×
10-year median
22.1×
Against its 10-year history
70th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.9× to 52.8×
Peer median
20.9×

Regeneron Pharmaceuticals' price to free cash flow is 26.6× as of Nov 3, 2026.

That is above its ten-year median of 22.1×, higher than on 70% of days in the last ten years.

Over that time it ranged from 7.9× in Jun 2022 to 52.8× in Nov 2016.

The median for 9 biotech stocks of a similar size is 20.9×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far26.3×15.5×26.3×
202519.5×15.4×22.9×
202422.8×21.6×39.7×
202320.8×15.5×23.5×
202215.5×7.9×16.4×
202112.6×12.2×42.9×
202032.6×18.6×42.5×
201920.5×15.3×28.6×
201824.1×22.2×35.9×
201749.2×43.6×49.2×
201646.2×35.6×81.3×
201589.7×77.0×260×
201478.2×66.5×100×
201392.6×90.1×136×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
REGNRegeneron Pharmaceuticals26.6×
VRTXVertex Pharmaceuticalsn/m
ONCBeOne Medicines30.2×
UTHRUnited Therapeutics23.7×
INCYIncyte12.7×
ALNYAlnylam Pharmaceuticals26.7×
EXELExelixis14.8×
NBIXNeurocrine Biosciences17.0×
HALOHalozyme Therapeutics18.2×
TECHBIO-TECHNE43.3×
Peer median20.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.